期刊文献+

帕金森病异动症发病的相关因素分析 被引量:5

Factors associated with development of dyskinesia in Parkinson's disease
下载PDF
导出
摘要 目的探讨帕金森病异动症(LID)发生的相关因素。方法应用统一帕金森病(PD)评分量表(UPDRS)第2、3部分和第4-A部分,Hoehn-Yahr分期评分共随访410例PD患者,将UPDRS量表第IV-A部分32项≥1分的患者纳入LID组,并与非LID组的年龄、性别、发病年龄、主要临床亚型、病程、使用多巴制剂的疗程及当前的治疗情况等因素进行统计分析。结果 410例帕金森病患者中的396例患者坚持规律服药2个月以上,并且其中的105例患者出现异动症,LID组与非LID组在性别、年龄、发病年龄、病程、使用左旋多巴疗程、剂量、Hoehn-Yahr分期及统一帕金森病评分量表第3部分评分之间差异有统计学意义。异动症相关的多因素Logistic回归分析显示,性别、年龄、发病年龄、病程及使用左旋多巴的日剂量是LID发生的独立危险因素。结论女性患者,年龄及发病年龄较轻,病程较长以及使用左旋多巴日剂量较大的帕金森病患者易发生异动症。 Objective To explore the factors related to dyskinesia in Parkinson's disease(PD).Methods The patients' score on the motor component and ability of daily living(Part 2 and 3)of the Unified Parkinson's Disease Rating Scale(UPDRS)and Hoehn-Yahr stage were recorded.Levodopa-induced dyskinesia(LID)was considered to be present if the patient had a score of 1 or more on item 32 of the UPDRS Part 4.Clinical data including age,gender,age at disease onset,initial clinical manifestation,duration of disease,time when Levodopa therapy was started,and current treatment were analyzed and compared between the two groups.Results Of the 410 cases with PD,396 patients received regular treatment with Levodopa for at least2 months,among which 105 patients developed LID by the end of the study.There were statistically significant differences in gender,age,age at onset of disease,duration of disease,duration and dose of Levodopa treatment,score on UPDRS part 3 and Hoehn-Yahr stage between the LID and non-LID groups.Multivariate logistic regression analysis showed that age,gender,age at onset of PD,duration of disease and dose of Levodopa were the independent risk factors of LID.Conclusions The results showed that the development of LID is more likely in young female patients with early onset of the disease,a longer duration of PD and a higher daily dose of Levodopa.
出处 《中国现代医学杂志》 CAS 北大核心 2016年第2期121-126,共6页 China Journal of Modern Medicine
关键词 帕金森病 异动症 危险因素 Parkinson's disease Levodopa-induced dyskinesia risk factor
  • 相关文献

参考文献22

  • 1Cenci MA, Lindgren HS. Advances in understanding L-DOPA- induced dyskinesia[J]. Current Opinion in Neurobiology, 2007, 17(6): 665-671.
  • 2Braak H, Ghebremedhin E, Rub U, et al. Stages in the develop- ment of Parkinson's diseaserelated pathology[J]. Cell Tissue Res, 2004, 318(1): 121-134.
  • 3Hughes A J, Daniel SE, Kilford L, et al. Accuracy of clinical di- agnosis of Parkinson's disease: a clinico-pathologicalstudy of 100 cases[J]. Psychiatry, 1992, 55: 181-184.
  • 4Judith AS, Arif D, Fredy J, et al. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease[J]. Mov Disord, 2006, 21: 654-659.
  • 5Lin JJ, Yueh KC, Lin SZ, et al. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse ef- fects in Parkinson's disease[J]. J Neurol Scien, 2007, 252: 130- 134.
  • 6Mariana R, Artur FS, Vivian A, et al. DRD2 haplotype is asso- ciated with dyskinesia induced by levodopa therapy in Parkin- son's disease patienls[J]. Pharmacogenomies, 2012, 13: 1701-1710.
  • 7Rajput AH, Voll A, Rajput ML, et al. Course in Parkinson dis- ease subtypes: A 39-year clinicopathologtc study[J]. Neurology, 2009, 73: 206-212.
  • 8Fahn S, Marsden CD, Calne DB, et al. Unified Parkinson's dis- ease rating scale[J]. New Jersey: Macmillan, 1987: 153-163.
  • 9Hanser RA, Zesiewicz TA, Factor SA, et al. Clinical trials of add-an medications in Parkinson's disease: Efficacy versus use- fulness[J]. Parkinsonism Relat Disord, 1997, 3: 1-6.
  • 10Gub W. AIMS: ECDEU assessment manual for psychopharma- eology[J]. US Washington, DC: Government Printing Office, 1976.

二级参考文献12

  • 1张颖冬.重视帕金森病的正确诊断——帕金森病与帕金森综合征诊断及鉴别诊断的现代认识[J].临床神经病学杂志,2007,20(5):321-325. 被引量:17
  • 2董青,李焰生.帕金森病非运动症状的研究进展[J].临床神经病学杂志,2008,21(4):310-312. 被引量:32
  • 3Chaudhuri KR, Healy DG, Schapira AH. Non motor symptoms of Parkinson's disease : diagnosis and management [ J ]. Lancet Neurol, 2006, 5: 235.
  • 4Chaudhuri KR, Martinez-Martin P, Sehapira AH, et al. International muhicenter pilot study of the first comprehensive self-completed non- motor symptoms questionnaire for Parkinson's disease: the Quest study[J]. Mov Disord ,2006,21:916.
  • 5Nistic R, Mehdawy B, Piccirilli S, et al. Paraquat and rotenone-in- duced models of Parkinson's disease[J]. Int J Immunopathol Phar- macol, 2011, 24: 313.
  • 6de Lau LM, Bornebroek M, Witteman JC. Dietary fatty acids and the risk of Parkinsou disease : the Rotterdam study [ J ]. Neurology, 2005, 64: 2040.
  • 7Miyake Y, Sasaki S, Tanaka K. Dietary fat intake and risk of Parkinson's disease :a case-control study in Japan[J ]. J Neurol Sci, 2010, 288: 117.
  • 8Ahlskog JE. Does vigorous exercise have a neuron-protective effect in Parkinson disease[ J]. Neurology, 2011, 77 : 258.
  • 9Cannon JR, Greenamyre JT. Neurotoxic in vivo models of Parkin- son's disease recent advances[ J]. Prog Brain Res, 2010, 184: 17.
  • 10干静,刘振国,周明珠,周桢源,应黎,陈伟.帕金森病患者非运动症状的研究[J].中华老年医学杂志,2008,27(6):409-412. 被引量:15

共引文献6

同被引文献27

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部